The systemic administration of IL‐10 in humans for the treatment of different pathologies (including inflammatory bowel disease, allergic asthma, and solid tumours) has been tested in different clinical trials but failed in the clinical outcome of these patients due to various problems (Saraiva et al, 2020). This evidence concerns the gene IL10 and inflammatory bowel disease.